
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2904160/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. Journal of Atherosclerosis and Thrombosis, 2022, 29, 608-638.	2.0	18
2	Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study. Journal of Atherosclerosis and Thrombosis, 2022, 29, 906-922.	2.0	13
3	Prospective Registry Study of Primary Dyslipidemia (PROLIPID): Rationale and Study Design. Journal of Atherosclerosis and Thrombosis, 2022, 29, 953-969.	2.0	6
4	Polygenic variants related to familial hypobetalipoproteinemia in a patient with Alzheimer's disease homozygotic for the APOE ε2 allele presenting multiple cortical superficial siderosis and recurrent lobar hemorrhages. Neurogenetics, 2022, 23, 69-71.	1.4	0
5	Podocyte-specific Transcription Factors: Could MafB become a Therapeutic Target for Kidney Disease?. Internal Medicine, 2022, , .	0.7	2
6	Association of collateral flow with clinical outcomes in patients with acute myocardial infarction. Heart and Vessels, 2022, 37, 1496-1505.	1.2	7
7	AAA-ATPase valosin-containing protein binds the transcription factor SREBP1 and promotes its proteolytic activation by rhomboid protease RHBDL4. Journal of Biological Chemistry, 2022, 298, 101936.	3.4	4
8	Response to letter by Dr. Yetkin: existence of coronary collateral vessels during acute myocardial infarction. Heart and Vessels, 2022, , .	1.2	0
9	Sex-specific Association of Primary Aldosteronism With Visceral Adiposity. Journal of the Endocrine Society, 2022, 6, .	0.2	1
10	Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. Journal of Atherosclerosis and Thrombosis, 2021, , .	2.0	7
11	Perfusion Balloon for the Treatment of Very Late Stent Thrombosis. International Heart Journal, 2021, 62, 422-426.	1.0	0
12	Clinical Factors Associated with Long Fluoroscopy Time in Percutaneous Coronary Interventions to the Culprit Lesion of Non-ST-Segment Elevation Myocardial Infarction. International Heart Journal, 2021, 62, 282-289.	1.0	6
13	Small Fibre Neuropathy Is Associated With Impaired Vascular Endothelial Function in Patients With Type 2 Diabetes. Frontiers in Endocrinology, 2021, 12, 653277.	3.5	11
14	A novel SOX10 nonsense mutation in a patient with Kallmann syndrome and Waardenburg syndrome. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	3
15	Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized doubleâ€blind placeboâ€controlled clinical trials. Cardiovascular Diabetology, 2021, 20, 96.	6.8	16
16	Normal plasma apoB48 despite the virtual absence of apoB100 in a compound heterozygote with novel mutations in the MTTP gene. Journal of Clinical Lipidology, 2021, 15, 569-573.	1.5	2
17	Recurrent Lobar Hemorrhages and Multiple Cortical Superficial Siderosis in a Patient of Alzheimer's Disease With Homozygous APOE ε2 Allele Presenting Hypobetalipoproteinemia and Pathological Findings of 18F-THK5351 Positron Emission Tomography: A Case Report. Frontiers in Neurology, 2021, 12, 645625.	2.4	2
18	Comparison of the effects of frequent versus conventional nutritional interventions in patients with typeÂ2 diabetes mellitus: A randomized, controlled trial. Journal of Diabetes Investigation, 2021, , .	2.4	3

#	Article	IF	CITATIONS
19	Glucose Effectiveness Decreases in Relationship to a Subtle Worsening of Metabolic Parameters in Young Japanese with Normal Glucose Tolerance. Metabolic Syndrome and Related Disorders, 2021, 19, 409-415.	1.3	0
20	Leptin sensitizing effect of 1,3-butanediol and its potential mechanism. Scientific Reports, 2021, 11, 17691.	3.3	8
21	Postloading insulinemia is independently associated with arterial stiffness in young Japanese persons. Hypertension Research, 2021, 44, 1515-1523.	2.7	3
22	Current Diagnosis and Management of Primary Chylomicronemia. Journal of Atherosclerosis and Thrombosis, 2021, 28, 883-904.	2.0	14
23	Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate. Journal of Atherosclerosis and Thrombosis, 2021, 28, 974-996.	2.0	10
24	Current Diagnosis and Management of Abetalipoproteinemia. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1009-1019.	2.0	21
25	Factors associated with difficulty in crossing the culprit lesion of acute myocardial infarction. Scientific Reports, 2021, 11, 21403.	3.3	4
26	Myeloid HMG-CoA Reductase Determines Adipose Tissue Inflammation, Insulin Resistance, and Hepatic Steatosis in Diet-Induced Obese Mice. Diabetes, 2020, 69, 158-164.	0.6	19
27	β-Cell–Specific Deletion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) Reductase Causes Overt Diabetes due to Reduction of β-Cell Mass and Impaired Insulin Secretion. Diabetes, 2020, 69, 2352-2363.	0.6	18
28	Peripheral circadian rhythms in the liver and white adipose tissue of mice are attenuated by constant light and restored by time-restricted feeding. PLoS ONE, 2020, 15, e0234439.	2.5	28
29	The Anti-atherogenic Activity of Beauveriolide Derivative BVD327, a Sterol <i>O</i> -Acyltransferase 2-Selective Inhibitor, in Apolipoprotein E Knockout Mice. Biological and Pharmaceutical Bulletin, 2020, 43, 951-958.	1.4	4
30	Insulin and Proinsulin Dynamics Progressively Deteriorate From Within the Normal Range Toward Impaired Glucose Tolerance. Journal of the Endocrine Society, 2020, 4, bvaa066.	0.2	8
31	Esterification of 4β-hydroxycholesterol and other oxysterols in human plasma occurs independently of LCAT. Journal of Lipid Research, 2020, 61, 1287-1299.	4.2	9
32	Longâ€ŧerm efficacy of the sodium–glucose cotransporterÂ2 inhibitor, ipragliflozin, in a case of typeÂA insulin resistance syndrome. Journal of Diabetes Investigation, 2020, 11, 1363-1365.	2.4	7
33	MON-210 Role of Female Gender and Subcutaneous Fat in the Positive Association of Obesity with Idiopathic Hyperaldosteronism. Journal of the Endocrine Society, 2020, 4, .	0.2	1
34	Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia. Journal of Atherosclerosis and Thrombosis, 2020, 27, 1246-1254.	2.0	3
35	Title is missing!. , 2020, 15, e0234439.		0

#	Article	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0234439.		Ο
38	Title is missing!. , 2020, 15, e0234439.		0
39	Case of acuteâ€onset type 1 diabetes induced by longâ€ŧerm immunotherapy with nivolumab in a patient with mucosal melanoma. Journal of Dermatology, 2019, 46, e463-e464.	1.2	6
40	Low hemoglobin A1c and low body mass index are associated with dementia and activities of daily living disability among Japanese nursing home residents with diabetes. Geriatrics and Gerontology International, 2019, 19, 854-860.	1.5	4
41	Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. International Journal of Molecular Sciences, 2019, 20, 5537.	4.1	27
42	Critical Role of SREBP-1c Large-VLDL Pathway in Environment-Induced Hypertriglyceridemia of Apo AV Deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 373-386.	2.4	11
43	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	6.8	104
44	Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52â€week data from the PROVIDE study. Diabetes, Obesity and Metabolism, 2019, 21, 1737-1744.	4.4	35
45	Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment. International Journal of Molecular Sciences, 2019, 20, 706.	4.1	53
46	Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study. Diabetes, Obesity and Metabolism, 2019, 21, 791-800.	4.4	15
47	Loss of ACAT1 Attenuates Atherosclerosis Aggravated by Loss of NCEH1 in Bone Marrow-Derived Cells. Journal of Atherosclerosis and Thrombosis, 2019, 26, 246-259.	2.0	3
48	SUN-096 Hypothalamic ATP Has a Crucial Role in the Pathogenesis of Leptin Resistance: A Potential Mechanism for the Amelioration of Leptin Resistance by Celastrol and Withaferin A. Journal of the Endocrine Society, 2019, 3, .	0.2	0
49	Effects of a novel selective peroxisome proliferatorâ€activated receptorâ€Î± modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. Journal of Diabetes Investigation, 2018, 9, 1323-1332.	2.4	32
50	Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care, 2018, 41, 1275-1284.	8.6	43
51	Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Diabetes Care, 2018, 41, 538-546.	8.6	122
52	Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. Journal of Atherosclerosis and Thrombosis, 2018, 25, 521-538.	2.0	97
53	Efficacy and safety of pemafibrate (K-877), aÂselective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. Journal of Clinical Lipidology, 2018, 12, 173-184.	1.5	127
54	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.	2.7	276

#	Article	IF	CITATIONS
55	Inflammasome Activation Aggravates Cutaneous Xanthomatosis and Atherosclerosis in ACAT1 (Acyl-CoA Cholesterol Acyltransferase 1) Deficiency in Bone Marrow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2576-2589.	2.4	15
56	Myeloid HMG-CoA (3-Hydroxy-3-Methylglutaryl-Coenzyme A) Reductase Determines Atherosclerosis by Modulating Migration of Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2590-2600.	2.4	23
57	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. Journal of Atherosclerosis and Thrombosis, 2018, 25, 846-984.	2.0	541
58	Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. Journal of Clinical Lipidology, 2018, 12, 1267-1279.e4.	1.5	35
59	A case with relapsed transient neonatal diabetes mellitus treated with sulfonylurea, ending chronic insulin requirement. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.5	1
60	4. Management of Disorders of Lipoprotein Metabolism-Update The Journal of the Japanese Society of Internal Medicine, 2018, 107, 453-457.	0.0	0
61	Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis, 2017, 261, 144-152.	0.8	101
62	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 951-964.	11.4	228
63	Role of Hormone-sensitive Lipase in Leptin-Promoted Fat Loss and Glucose Lowering. Journal of Atherosclerosis and Thrombosis, 2017, 24, 1105-1116.	2.0	6
64	Cardio-Ankle Vascular Index and Indices of Diabetic Polyneuropathy in Patients with Type 2 Diabetes. Journal of Diabetes Research, 2017, 2017, 1-8.	2.3	15
65	Defeating the Invisible Enemies. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 679-681.	0.0	0
66	Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis, 2016, 249, 36-43.	0.8	146
67	Maximum BMI and microvascular complications in a cohort of Japanese patients with type 2 diabetes: the Japan Diabetes Complications Study. Journal of Diabetes and Its Complications, 2016, 30, 790-797.	2.3	9
68	Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report. Journal of Clinical Lipidology, 2016, 10, 1045-1049.	1.5	14
69	Ankle-brachial index and eicosapentaenoic acid/arachidonic acid ratio in smokers with type 2 diabetes mellitus. Tobacco Induced Diseases, 2016, 14, 2.	0.6	1
70	The β-cell GHSR and downstream cAMP/TRPM2 signaling account for insulinostatic and glycemic effects of ghrelin. Scientific Reports, 2015, 5, 14041.	3.3	48
71	Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver. Journal of Lipid Research, 2015, 56, 998-1005.	4.2	14
72	Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy. Biochemical and Biophysical Research Communications, 2015, 466, 536-540.	2.1	59

#	Article	IF	CITATIONS
73	New Pyripyropene A Derivatives, Highly SOAT2-Selective Inhibitors, Improve Hypercholesterolemia and Atherosclerosis in Atherogenic Mouse Models. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 297-307.	2.5	17
74	Metabolic Syndrome. Journal of Atherosclerosis and Thrombosis, 2014, 21, 1-5.	2.0	14
75	Lipoprotein Subfractions Highly Associated With Renal Damage in Familial Lecithin:Cholesterol Acyltransferase Deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1756-1762.	2.4	21
76	Critical role of neutral cholesteryl ester hydrolase 1 in cholesteryl ester hydrolysis in murine macrophages. Journal of Lipid Research, 2014, 55, 2033-2040.	4.2	33
77	Eicosapentaenoic acid/arachidonic acid ratio and smoking status in elderly patients with type 2 diabetes mellitus. Diabetology and Metabolic Syndrome, 2014, 6, 85.	2.7	6
78	Absence of Nceh1 augments 25-hydroxycholesterol-induced ER stress and apoptosis in macrophages. Journal of Lipid Research, 2014, 55, 2082-2092.	4.2	38
79	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atherosclerosis Supplements, 2014, 15, 1-15.	1.2	83
80	The effects of partial use of formula diet on weight reduction and metabolic variables in obese type 2 diabetic patients—Multicenter trial. Obesity Research and Clinical Practice, 2013, 7, e43-e54.	1.8	20
81	Liver-Specific Deletion of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Causes Hepatic Steatosis and Death. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1824-1831.	2.4	38
82	Cross-Sectional Survey to Assess the Status of Lipid Management in High-Risk Patients With Dyslipidemia: Clinical Impact of Combination Therapy With Ezetimibe. Current Therapeutic Research, 2012, 73, 1-15.	1.2	18
83	The correlation of common carotid arterial diameter with atherosclerosis and diabetic retinopathy in patients with type 2 diabetes mellitus. Acta Diabetologica, 2012, 49, 63-68.	2.5	27
84	Abrogation of neutral cholesterol ester hydrolytic activity causes adrenal enlargement. Biochemical and Biophysical Research Communications, 2011, 404, 254-260.	2.1	12
85	The Role of Neutral Cholesterol Ester Hydrolysis in Macrophage Foam Cells. Journal of Atherosclerosis and Thrombosis, 2011, 18, 359-364.	2.0	57
86	Depot-Specific Expression of Lipolytic Genes in Human Adipose Tissues. Journal of Atherosclerosis and Thrombosis, 2011, 18, 190-199.	2.0	35
87	Molecular Analysis of a Novel LCAT Mutation (Gly179 → Arg) Found in a Patient with Complete LCAT Deficiency. Journal of Atherosclerosis and Thrombosis, 2011, 18, 713-719.	2.0	5
88	The Measurement of Proinsulin Level, But Not Insulin, is Useful for Diagnosis of Insulinoma The Journal of the Japanese Society of Internal Medicine, 2010, 99, 2545-2547.	0.0	0
89	Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mammalian Genome, 2010, 21, 427-441.	2.2	147
90	The Critical Role of Neutral Cholesterol Ester Hydrolase 1 in Cholesterol Removal From Human Macrophages. Circulation Research, 2010, 107, 1387-1395.	4.5	90

#	Article	IF	CITATIONS
91	Targeting of neutral cholesterol ester hydrolase to the endoplasmic reticulum via its N-terminal sequence. Journal of Lipid Research, 2010, 51, 274-285.	4.2	27
92	Effects of hormone-sensitive lipase disruption on cardiac energy metabolism in response to fasting and refeeding. American Journal of Physiology - Endocrinology and Metabolism, 2009, 297, E1115-E1124.	3.5	19
93	Relationship between upper limb peripheral artery stiffness using the radial artery and atherosclerotic parameters. Journal of Medical Ultrasonics (2001), 2009, 36, 129-135.	1.3	2
94	Ablation of Neutral Cholesterol Ester Hydrolase 1 Accelerates Atherosclerosis. Cell Metabolism, 2009, 10, 219-228.	16.2	93
95	Hormone-sensitive lipase deficiency suppresses insulin secretion from pancreatic islets of Lep/ mice. Biochemical and Biophysical Research Communications, 2009, 387, 511-515.	2.1	8
96	Identification of Neutral Cholesterol Ester Hydrolase, a Key Enzyme Removing Cholesterol from Macrophages. Journal of Biological Chemistry, 2008, 283, 33357-33364.	3.4	104
97	Hormone-sensitive lipase is involved in hepatic cholesteryl ester hydrolysis. Journal of Lipid Research, 2008, 49, 1829-1838.	4.2	51
98	Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver. Journal of Lipid Research, 2006, 47, 1950-1958.	4.2	32
99	Identification of a Novel Member of the Carboxylesterase Family That Hydrolyzes Triacylglycerol: A Potential Role in Adipocyte Lipolysis. Diabetes, 2006, 55, 2091-2097.	0.6	73
100	Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. European Journal of Cancer, 2005, 41, 1316-1322.	2.8	220
101	Absence of Hormone-sensitive Lipase Inhibits Obesity and Adipogenesis in Lep Mice. Journal of Biological Chemistry, 2004, 279, 15084-15090.	3.4	55
102	Early Embryonic Lethality Caused by Targeted Disruption of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Gene. Journal of Biological Chemistry, 2003, 278, 42936-42941.	3.4	94
103	Resistance to high-fat diet-induced obesity and altered expression of adipose-specific genes in HSL-deficient mice. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E1182-E1195.	3.5	142
104	Absence of Sterol Regulatory Element-binding Protein-1 (SREBP-1) Ameliorates Fatty Livers but Not Obesity or Insulin Resistance in Lep/Lep Mice. Journal of Biological Chemistry, 2002, 277, 19353-19357.	3.4	327
105	Adrenal Neutral Cholesteryl Ester Hydrolase: Identification, Subcellular Distribution, and Sex Differences. Endocrinology, 2002, 143, 801-806.	2.8	58
106	Lipolysis in the Absence of Hormone-Sensitive Lipase: Evidence for a Common Mechanism Regulating Distinct Lipases. Diabetes, 2002, 51, 3368-3375.	0.6	111
107	Elimination of Cholesterol Ester from Macrophage Foam Cells by Adenovirus-mediated Gene Transfer of Hormone-sensitive Lipase. Journal of Biological Chemistry, 2002, 277, 31893-31899.	3.4	35
108	Adrenal Neutral Cholesteryl Ester Hydrolase: Identification, Subcellular Distribution, and Sex Differences. Endocrinology, 2002, 143, 801-806.	2.8	16

#	Article	IF	CITATIONS
109	Direct effect of an acylâ€CoA:cholesterol acyltransferase inhibitor, Fâ€1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. British Journal of Pharmacology, 2001, 133, 1005-1012.	5.4	28
110	Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 372-377.	2.4	327
111	Lipoprotein(a) and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1-2.	2.4	41
112	Hyperthyroidism Presenting as Dysphagia Internal Medicine, 2000, 39, 472-473.	0.7	26
113	Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia. Journal of Lipid Research, 2000, 41, 1199-1204.	4.2	77
114	Presence of telomeric G-strand tails in the telomerase catalytic subunit TERT knockout mice. Genes To Cells, 1999, 4, 563-572.	1.2	94
115	Absence of Cd36 mutation in the original spontaneously hypertensive rats with insulin resistance. Nature Genetics, 1999, 22, 226-228.	21.4	59
116	Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. The Journal of Japan Atherosclerosis Society, 1998, 25, 427-429.	0.0	0
117	The Effect of Hyperinsulinemia and Insulin Resistance on Atherosclerosis in Rats with Transplanted Pancreas and In Insulin Receptor Substrate-1 (IRS-1) Knockout Mouse. The Journal of Japan Atherosclerosis Society, 1997, 24, 505-508.	0.0	0
118	Comparative Studies of Atherosclerosis by Using Genetically Engineered Murine Models. The Journal of Japan Atherosclerosis Society, 1997, 24, 477-480.	0.0	0
119	Synergistic effects of transforming growth factor-Î ² on the expression ofc-fms, macrophage colony-stimulating factor receptor gene, in vascular smooth muscle cells. FEBS Letters, 1996, 399, 207-210.	2.8	5
120	Rapid genotyping of low density lipoprotein receptor knockout mice using a polymerase chain reaction technique. Laboratory Animals, 1995, 29, 447-449.	1.0	27
121	Effect of Monocyte Colony-Stimulating Factor (M-CSF) on Lipoprotein Metabolism. Annals of the New York Academy of Sciences, 1990, 598, 556-557.	3.8	1
122	Augmentation by heparin of endothelial cell proliferation in vitro Blood & Vessel, 1985, 16, 508-513.	0.0	1
123	A CASE OF POLYMYOSITIS ASSOCIATED WITH HYPERTRIGLYCERIDEMIA. The Journal of the Japanese Society of Internal Medicine, 1984, 73, 368-373.	0.0	0